Pravadoline (WIN 48098) is a cyclooxygesase inhibitor and inhibits prostaglandin synthesis with IC50 of 4.9 μM, also a cannabinoid agonist.
TG101348 is a selective small-molecule Janus kinase 2 (JAK2) inhibitor with IC50 of 3 nM.
NS-3-008 hydrochloride is an orally active transcriptional inhibitor of G0/G1 switch 2 (G0s2) with an IC50 of 2.25 μM.
Itaconic acid (Itaconate) acts as a comonomer in the polymerization of polyacrylonitrile (PAN) to promote the thermo-oxidative stabilization of polymer.
Afuresertib (GSK2110183; LAE002) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively.
MRTX1133 is a first-in-class, potent and highly selective KRAS G12D inhibitor. MRTX1133 targets the KRAS G12D protein in both active and inactive states. MRTX1133 selectively inhibits KRAS G12D mutant, but not KRAS wild-type, tumor cells.
UNC1999 is a potent, orally bioavailable and selective inhibitor of EZH2 and EZH1 with IC50 of 2 nM and 45 nM, respectively, showing >1000-fold selectivity over a broad range of epigenetic and non-epigenetic targets.
Juglanin, a natural occurring flavonoid, is a JNK acticator, with inflammation and anti-tumor activities. Juglanin can induce apoptosis and autophagy on human breast cancer cells.
Ezetimibe (Zetia) is a beta-lactam analog that targets NPC1L1, thereby lowering blood cholesterol levels. In addition, Ezetimibe can prevent spinal cord injury by inhibiting apoptosis through activation of autophagy and modulation of the PI3K/AKT/mTOR signaling pathway, which can be used in studies related to spinal cord injury.